China Medical System Holdings Limited announced that on Mar, 4 2026 China’s National Medical Products Administration approved the company’s application to start clinical trials of CMS-D008, a self-developed INHBE-targeting small nucleic acid (siRNA) injection for overweight and obese individuals.

CMS-D008 is designed for subcutaneous administration and works by reducing hepatic expression of the inhibin subunit beta E gene (INHBE), thereby lowering Activin E protein levels to inhibit Activin E-ALK7 signaling and decrease fat accumulation. Preclinical studies showed the candidate produced sustained INHBE suppression, enhanced weight loss through fat-mass reduction while preserving lean mass, and exhibited a favorable safety profile.

The company said CMS-D008 may complement its GLP-1R/GCGR dual agonist CMS-D005, which is in clinical development for weight loss and liver fat reduction. The two investigational drugs could potentially offer combined, long-term benefits in obesity and metabolic disease management.

China Medical System is preparing to launch the approved clinical trials and aims to accelerate development and commercialization using its existing cardiovascular and metabolic-disease network. The company advised shareholders and investors to exercise caution when dealing in its securities.